Meeting
2011 ASCO Annual Meeting
Phase I clinical trial of VTX-2337, a selective toll-like receptor 8 (TLR8) agonist, in patients with advanced solid tumors.
Authors
P. A. Cohen
Mayo Clinic, Scottsdale, AZ
P. A. Cohen , D. W. Northfelt , G. J. Weiss , D. D. Von Hoff , K. Manjarrez , G. Dietsch , R. M. Hershberg , R. K. Ramanathan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Developmental Therapeutics - Clinical Pharmacology and Immunotherapy
Track
Developmental Therapeutics
Sub Track
Immunotherapy and Biologic Therapy
Clinical Trial Registration Number
NCT00688415
Citation
J Clin Oncol 29: 2011 (suppl; abstr 2537)
Abstract #
2537
Poster Bd #
23
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
A phase I study to assess safety, pharmacokinetics (PK), and pharmacodynamics (PD) of JNJ-64457107, a CD40 agonistic monoclonal antibody, in patients (pts) with advanced solid tumors.
First Author: Emiliano Calvo
Poster
2017 ASCO Annual Meeting
Phase I study to evaluate the tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) of PM01183 (Lurbinectedin) in combination with olaparib in patients with advanced solid tumors.
First Author: Andres Poveda
Poster
2014 ASCO Annual Meeting
A phase 1 first-in-human study of XMT-1107, a polymer-conjugated fumagillol derivative, in patients (pts) with advanced solid tumors.
First Author: Johanna C. Bendell
Poster
2024 ASCO Annual Meeting
Preliminary results of a phase 1 study of Decoy20, an intravenous, killed, multiple immune receptor agonist bacterial product in patients with advanced solid tumors.
First Author: Roger J. Waltzman